公开(公告)号：US20240425612A1

公开(公告)日：2024-12-26

申请号：US18702227

申请日：2022-10-17

Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Sang Taek JUNG ,  Munsu KYUNG ,  Sanghwan KO ,  Migyeong JO ,  Suyeon KIM ,  Woo Hyung KO

IPC: C07K16/32 ,  A61K47/68

Abstract: Provided are Fc variants having improved half-life by binding to and unbinding from FcRn in a pH-dependent manner, which have improved capacity to selectively bind to Fcγ receptors. The human Fc domain variants have lower capacity to bind to immune-inhibiting receptor FcγRIIb and have higher capacity to bind to immune activating receptor FcγRIIIa (increased A/I ratio) than a wild-type human antibody Fc domain and conventional antibodies approved as antibody therapeutic agents, thereby having remarkably improved ADCC induction ability and having maximized half-life in blood in which excellent pH-selective FcRn binding and unbinding capacity is exhibited, and thus bind to numerous peptide drug therapeutics having a low half-life and retention time in the body to enable the peptide drug therapeutics to have an increased blood half-life and exhibit long-term drug efficacy, and can maximize the immune mechanism of therapeutic protein drugs to be effectively used as an improved antibody drug.